血脂康对高脂血症患者血小板活性及纤溶活性的影响  

The effects of Xuezhikang treatment on platelet actirity and fibrinolytic activity in patients with combined hyperlipidema

作　　者：蔡树霞[1] 孙薇[1] 

机构地区：[1]烟台市烟台山医院,山东烟台264001

出　　处：《山东医药》2003年第28期6-8,共3页Shandong Medical Journal

摘　　要：目的　探讨高脂血症患者血小板活性及纤溶活性的改变 ,观察血脂康对血小板活性和纤溶活性的影响。方法　选择 30例混合型高脂血症患者和 2 0例健康者 ,测定其血浆血小板 α-颗粒膜蛋白 14 0 (GMP- 14 0 )含量、血浆组织型纤溶酶原激活物 (t- PA)、t- PA抑制物 (PAI)活性及血脂指标。患者口服血脂康 8周后 ,比较治疗前后血浆 GMP- 14 0含量、t- PA、PAI活性及血清血脂的变化。结果　与对照组比较 ,患者组治疗前血清 TC、TG、低密度脂蛋白胆固醇 (L DL- C)明显增高 (P均 <0 .0 1) ,高密度脂蛋白胆固醇 (HDL- C)降低 (P <0 .0 1)。血浆GMP- 14 0含量、PAI活性明显升高 (P均 <0 .0 1) ,t- PA活性降低 (P <0 .0 1)。经血脂康治疗 8周后 ,患者组血清TC、TG、L DL - C明显降低 (P均 <0 .0 1) ,HDL - C升高 (P <0 .0 5 ) ,血浆 GMP- 14 0含量明显下降 (P <0 .0 1) ,t-PA及 PAI活性无显著改善 (P >0 .0 5 )。PAI活性与血清 TG呈正相关 (r=0 .4 6 ,P <0 .0 5 )。结论　高脂血症患者血小板活性明显增加 ,GMP- 14 0含量升高 ,纤溶活性明显降低。血脂康通过降低血清 TC、TG及 L DL - C,抑制血小板活化 ,减少血小板标志物 GMP- 14 0的表达 。Objective To study the change of platelet activity marker GMP-140 and fibrinolytic activity in combined hyperlipidemic patients;to investigate the effects of Lipid-lowering therapy with Xuezhikang on GMP-140 concentration and fibrinolytic activity.Methods Thirty combined hyperlipidemic patients and twenty healthy volunteers participated in the study.Serum Lipid level、plasma GMP-140 concentration,t-PA activity and PAI activity were measured in all subjects.Then hyperlipidemic patients were treated with Xuezhikang for 8 weeks.At the end of 8 weeks treatment with Xuezhikang,serum Lipid level,plasma GMP-140 concentration,t-PA activity and PAI activity were remeasured.Results Compared with normal control group,hyperlipidemic patients showed,HDL-C was reduced significantly(P<0.01);the plasma GMP-140 concentration and PAI activity were markedly elevated(P<0.01),while t-PA activity was reduced (P<0.01)in hyperlipidemic patients.After 8 weeks treatment with Xuezhikang,there was an expected therapeutic effect on serum Lipid concentration:triglyceride andcholesterol concentration( total cholesterol and LDL-C) was reduced (all P<0.01),while HDL-C was elevated (P<0.05),plasma GMP-140 concentration was reduced(P<0.01),while t-PA activity and PAI activity were not improved.PAI activity was positive related to serum triglyceride concentration.Conclusion Combined hyperlipidemic patients showed elevated platelet activity and hypofibrinolytic activity.Xuezhikang can reduce serum Lipid,inhibit platelet acitivity,reduce plasma GMP-140 concentration,but there was no significant improvement of fibrinolytic acitivity in combined hyperlipidemic patients.

关 键 词：血脂康 高脂血症 血小板活性 纤溶活性 血清 低密度脂蛋白胆固醇 高密度脂蛋白胆固醇 

分 类 号：R589.2[医药卫生—内分泌] R972.6[医药卫生—内科学]